The company estimates the global market for rose bengal sodium-based ophthalmic therapies at more than USD 20 billion.
How RB-PDAT works and clinical background
RB-PDAT pairs rose bengal sodium with green-light activation to generate reactive oxygen species intended to inactivate pathogens on the cornea.
Clinical track record cited includes more than 280 treated patients; REAGIR Phase 3 missed its primary endpoint versus natamycin in the overall population.
VisiRose selected for ESCRS iNovation Day 2026
VisiRose, Provectus Biopharmaceuticals’ clinical-stage ophthalmology subsidiary, was selected to present RB-PDAT at ESCRS iNovation Day 2026 in London.
The showcase slot targets infectious keratitis, positioning RB-PDAT as a broad-spectrum photodynamic antimicrobial designed to avoid drug-resistance pathways.
PVCT•
